Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients
An agent that improves cardiac function without impacting systolic BP would be a welcome addition, experts say.
An agent that improves cardiac function without impacting systolic BP would be a welcome addition, experts say.
Either intervention alone improved health in a small trial, but the best results occurred when the two were used together.
Either intervention alone improved health in a small trial, but the best results occurred when the two were used together.
Procedural complications and short-term mortality were higher with concomitant procedures, but mortality to 3 years was not.
While the tool can be helpful for ruling out ACS in those with acute chest pain, clinical judgement should always prevail.
Several surgeons told TCTMD they’re highly critical of the trend, saying it’s time for an RCT of TAVI vs SAVR in those below age 65.
The conclusion is consistent with the FDA’s review of the issue.
If the LV is likely to improve or normalize with TAVI, there’s no reason not to treat, says Guy Witberg. But for some TAVI might…
As a slew of new catheter-based devices hit the market, it will be crucial to keep tabs on eligibility, safety, and access, experts say.
Black, Hispanic, and white sexual-minority women each have distinct risk profiles, speaking to the need for tailored care.
Interventionalists say it’s now time to make a dent in the complication rate, whether by strict protocols or smaller devices.